Three-dose vaccine prevents HIV patients getting hepatitis B
European Pharmaceutical Review
OCTOBER 21, 2022
Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus.
73 
Let's personalize your content